Angiogenic inhibitors: A new therapeutic strategy in oncology

Nature Clinical Practice Oncology

Volumn 2, Issue 11, 2005, Pages 562-577

  Gasparini, Giampietro ^a,d   Longo, Raffaele ^a   Toi, Masakazu ^b   Ferrara, Napoleone ^c  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c GENENTECH INC   (United States)

^d Division of Medical Oncology   (Italy)

Author keywords

Antiangiogenic therapy; Bevacizumab; SU11248; Tyrosine kinase inhibitors; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VATALANIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ATAXIA; BLEEDING; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; EDEMA; ENDOTHELIUM; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEADACHE; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; MALAISE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QT PROLONGATION; REVIEW; SOMNOLENCE; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR GROWTH; VOMITING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RESEARCH DESIGN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28444476260     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0342     Document Type: Review

References (99)

1. Bergers G and Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410
2. Folkman J and Hochberg M (1973) Self-regulation of growth in three dimensions. J Exp Med 138: 745-753
3. Longo R et al. (2002) Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 5: 237-256
4. St Croix B et al. (2000) Genes expressed in human tumor and endothelium. Science 289: 1197-1202
5. Pepper MS (2001) Role of the matrix metalloproteinases and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thrombovasc Biol 21: 1104-1117
6. Stupack DG and Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64: 207-238
7. Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043
8. Hicklin DJ and Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027
9. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927
10. Nyberg P et al. (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979
11. Jain RK et al. (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62
12. Vermeulen PB et al. (1995) Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 6: 59-64
13. Gasparini G and Harris AL (1995) Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782
14. Brown LF et al. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041-1056
15. Folkman J (2002) Looking for a good endothelial address. Cancer Cell 3: 113-115
16. Kerbel RS (2001) Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 19 (Suppl 18): S45-S51
17. Yu JL et al. (2002) Effect of p53 status on tumor response to anti-angiogenic therapy. Science 295: 1526-1528
18. Tran J et al. (2002) A role f or survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99: 4349-4354
19. Yu JL et al. (2001) Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 158: 1325-1334
20. Carmeliet P et al. (1998) Role of HIF-1 alpha in hypoxic-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490
21. Ferrara N et al. (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803
22. Ferrara N et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400
23. Jain RK (2005) Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology 19 (Suppl 3): S7-S16
24. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
25. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 350: 2335-2342
26. Johnson DH et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191
27. Miller KD et al. (2005) Randomized phase III trial of Capecitabine compared with Bevacizumab plus Capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799
28. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434
29. Sandler AB et al. (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial- E 4599 [abstract #4]. J Clin Oncol 23 (Suppl 16S)
30. Giantonio BJ et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract #2]. Proc Am Cancer Soc 23
31. Kuenen BC et al. (2002). Dose-finding and pharmacokinetics study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol 20: 1657-1667
32. Harris AL (2000) Von Hippel-Landau syndrome: Target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist 5 (Suppl 1): S32-S36
33. Raymond E et al. (2003) Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-targeted tyrosine kinase inhibitor, in patients with advanced cancers [abstract #769]. Proc Am Soc Clin Oncol 22
34. Manning WC et al. (2003) Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumor (GIST) [abstract #768]. Proc Am Soc Clin Oncol 22
35. O'Farrell A-M et al. (2003) Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies [abstract #939]. Proc Am Soc Clin Oncol 22
36. Toner GC et al. (2003) PET imaging study of SU11248 in patients with advanced malignancies [abstract #767]. Proc Am Soc Clin Oncol 22
37. Motzer RJ et al. (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) [abstract #4508]. Proc Am Soc Clin Oncol 23
38. Steward WP et al. (2003) Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer [abstract #1098]. Proc Am Soc Clin Oncol 22
39. Trarbach T et al. (2003) Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer [abstract #1144]. Proc Am Soc Clin Oncol 22
40. George D et al. (2003) Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma [abstract #1548]. Proc Am Soc Clin Oncol 22
41. Hecht JR et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/ 5-fluorouracil/leucovorin and PTK 787/ZK 222584 or placebo (CONFIRM-1) [abstract #3]. Proc Am Cancer Soc 23
42. Minami H et al. (2003) A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors [abstract]. Proc Am Soc Clin Oncol 22: 778
43. Miller KD et al. (2005) A multicenter phase II trial of ZD 6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11: 3369-3376
44. Strumberg D et al. (2005) Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972
45. Wilhelm SM et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinase involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
46. Ratain MJ et al. (2005) Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract #4544]. Proc Am Soc Clin Oncol 23
47. Ahmad T et al. (2004) BAY 43-9006 in patients with advanced melanoma [abstract #7506]. Proc Am Soc Clin Oncol 22
48. Bergsland EK (2004) Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm 61 (Suppl 5): S12-S20
49. Dupont J et al. (2003) Phase I study of VEGF Trap in patients with solid tumors and lymphoma [abstract #194]. Proc Am Soc Clin Oncol 22
50. Dupont J et al. (2005) Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. [abstract]. Proc Am Soc Clin Oncol 23: 3029
51. Coussens LM et al. (2002) Matrix metalloproteinase inhibitors and cancer trials and tribulations. Science 295: 2387-2392
52. Leighl NB et al. (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23: 2831-2839
53. Eder JP et al. (2002) Phase I clinical trial of recombinant human Endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772-3784
54. Herbst RS et al. (2002) Phase I study of recombinant human Endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803
55. Thomas JP et al. (2003) A Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21: 223-231
56. Heymach J et al. (2003) Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin [abstract #979]. Proc Am Soc Clin Oncol 22
57. Kulke M et al. (2003) A phase II, open-label, safety, pharmacokinetic and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors [abstract #958]. Proc Am Soc Clin Oncol 22
58. Eisterer W et al. (2002) Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 5: 352-359
59. Tjin Tham Sjin RM et al. (2005) A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65: 3656-3663
60. Morbidelli L et al. (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 9: 5358-5369
61. Wickstrom SA et al. (2004) An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 279: 20178-20185
62. Kuo CJ et al. (2001) Oligomerization-dependent regulation of motility and morphogenesis by collagen XVIII NC1/endostatin domain. J Cell Biol 152: 1233-1246
63. Gasparini G et al. (2001) Thalidomide: An old sedative-hypnotic with anticancer activity? Current Opin Invest Drugs 2: 1302-1308
64. Morabito A et al. (2005) Thalidomide is inactive in heavily pretreated metastatic breast cancer patients. Cancer J 11: 243-246
65. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
66. Barlogie B et al. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase-2 study of 169 patients. Blood 98: 492-494
67. Chang W J et al. (2005) Targeted therapy in multiple myeloma. Cancer Control 12: 91-104
68. Rajkumar SV et al. (2001) Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15: 1274-1276
69. Rajkumar SV et al. (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17: 775-779
70. Weber D et al. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16-19
71. Motzer RJ et al. (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20: 302-306
72. Morabito A et al. (2004) Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 11: 93-95
73. Drake MJ et al. (2003) An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88: 822-827
74. Tseng JE et al. (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92: 2364-2373
75. Fine HA et al. (2003) Phase II trial of Thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21: 2299-2304
76. Hwu WJ et al. (2002) Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20: 2610-2615
77. Lenz HJ et al. (2005) Antiangiogenic agents in cancer therapy. Oncology 19 (Suppl 3): S17-S25
78. Richardson P (2004) Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma. J Clin Oncol 22: 3212-3114
79. List A et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352: 549-557
80. Gasparini G et al. (2003) COX-2 inhibitors (Coxibs): A new class of anticancer agents? Lancet Oncol 4: 605-615
81. Altorki NK et al. (2003) Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21: 2645-2650
82. Gasparini G et al. The combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective anti-COX-2 rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. Oncologist, in press
83. Gasparini G et al. (2005) The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: A phase II study with biological correlates. Cancer J 11: 209-216
84. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102
85. Solomon S et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080
86. Nussmeir NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091
87. Dittaldi R et al. (2001) Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 16: 87-96
88. Beaudry P et al. (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD 6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as surrogate marker of antiangiogenic activity. Clin Cancer Res 11: 3514-3522
89. Shaked Y et al. (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of angiogenesis. Cancer Cell 7: 101-111
90. Schneider M et al. (2005) A surrogate marker to monitor angiogenesis at last. Cancer Cell 7: 3-4
91. Betensky RA et al. (2002) Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20: 2495-2499
92. Fox E et al. (2002) Clinical trial design for target-based therapy. Oncologist 7: 401-409
93. Gasparini G and Gion M (2000) Molecular-targeted anticancer therapy: challenges related to study-design and choice of proper end-points. Cancer J 6: 117-131
94. Bertolini F et al. (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346
95. Hobson B and Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: Continuous labelling studies. Br J Cancer 49: 405-413
96. Hudis CA et al. (2005) Clinical implications of antiangiogenic therapies. Oncology 19 (Suppl 3): S26-S31
97. Klement G et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24
98. Garcia AA et al. (2005) Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A Californian Cancer Consortium Trial. [abstract #5000]. Proc Am Soc Clin Oncol 23
99. Pennacchietti S et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361